Drug Patents owned by Janssen Therap
1. Drug name - SIRTURO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7498343 | JANSSEN THERAP | Mycobacterial inhibitors |
Dec, 2026
(4 years from now) | |
| US8546428 | JANSSEN THERAP | Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol |
Mar, 2029
(6 years from now) | |
| CN101547904A | JANSSEN THERAP | Fumarate Salt Of (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol |
Dec, 2015
(6 years ago) | |
| CN1671667A | JANSSEN THERAP | Quinoline Derivatives And Their Use As Mycobacterial Inhibitors |
Jul, 2023
(9 months from now) | |
| CN101070304B | JANSSEN THERAP | Quinoline Derivatives And Their Use As Mycobacterial Inhibitors |
Jul, 2023
(9 months from now) | |
| CN1325475C | JANSSEN THERAP | Quinoline Derivatives And Their Use As Mycobacterial Inhibitors |
Jul, 2023
(9 months from now) | |
| CN101070304A | JANSSEN THERAP | Quinoline Derivant And Its Application Used As Mycobacterium Inhibitor |
Jul, 2023
(9 months from now) | |
| IN236811B | JANSSEN THERAP | A Novel Substituted Quinoline Compound |
Jul, 2023
(9 months from now) | |
| IN200500220P1 | JANSSEN THERAP | A Novel Substituted Quinoline Compound |
Jul, 2023
(9 months from now) | |
| EP2301544B1 | JANSSEN THERAP | Quinoline Derivatives As Intermediates To Mycobacterial Inhibitors |
Jul, 2023
(9 months from now) | |
| EP2301544A1 | JANSSEN THERAP | Quinoline Derivatives As Intermediates To Mycobacterial Inhibitors |
Jul, 2023
(9 months from now) | |
| EP2086940A1 | JANSSEN THERAP | Fumarate Salt Of (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol |
Dec, 2027
(5 years from now) | |
| EP2086940B1 | JANSSEN THERAP | Fumarate Salt Of (Alpha S, Beta R)-6-Bromo-Alpha-[2-(Dimethylamino)Ethyl]-2-Methoxy-Alpha-1-Naphthalenyl-Beta-Phenyl-3-Quinolineethanol |
Dec, 2027
(5 years from now) | |
| EP1527050B1 | JANSSEN THERAP | Quinoline Derivatives And Their Use As Mycobacterial Inhibitors |
Jul, 2028
(5 years from now) | |
| EP1527050A1 | JANSSEN THERAP | Quinoline Derivatives And Their Use As Mycobacterial Inhibitors |
Jul, 2028
(5 years from now) | |
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | TABLET;ORAL | Prescription |
| EQ 100MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.